NuGen Medical Devices Inc. announced it has received its first bulk purchase order from Science-Link Trading SAPI de CV ("Science-Link"), a company in Mexico, for the Mexican market for 500 units of the Company's needle-free InsuJet™? injector device. The initial bulk purchase order for the 500 InsuJet™?

devices is to be pre-paid in full prior to delivery. NuGen is pleased to further report its distribution agreement with Science-Link targets the sale of 2,500 InsuJet™? needle-free injectors in 2023, and 5,000 needle-free injectors in 2024.

NuGen confirms the purchase order for 500 needle-free injectors will be pre- paid in full prior to delivery and has commenced registration of InsuJet™? in Mexico as a medical device, expected completion in four months which the sale is contingent upon. Including daily consumables, the total sale value of NuGen's agreement with Science-Link in 2023 and 2024 would be approximately USD 6.2 million with estimated gross margins of 72%.

Mexico is a large diabetes market globally as an estimated 1 in 6 adults are now living with diabetes1. In 2021, the estimated adult diabetic population grew to 14 million patients - a rise of 10% in the last 2 years. Diabetes-related health expenditure in Mexico has reached USD 20 billion, putting it in the top ten countries or territories with the total health expenditure.